An International, multicenter, randomized, partially-blinded clinical study of efficacy, safety, and optimal dosage selection of VM-1500 versus Efavirenz within the background of standard basic antiretroviral therapy, consisting of two nucleoside/nucleotide reverse transcriptase inhibitors, in HIV-1 infected treatment-naïve patients

Trial Profile

An International, multicenter, randomized, partially-blinded clinical study of efficacy, safety, and optimal dosage selection of VM-1500 versus Efavirenz within the background of standard basic antiretroviral therapy, consisting of two nucleoside/nucleotide reverse transcriptase inhibitors, in HIV-1 infected treatment-naïve patients

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Elsulfavirine (Primary) ; Efavirenz
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top